ArticleAdvances in experimental medicine and biology2026
Clinical and Molecular Genetic Study of an Alagille Syndrome Type 1 Case.
Article in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlagille syndrome (ALGS) is a rare autosomal dominant disorder with several clinical manifestations including facial, hepatic, cardiovascular, skeletal, and renal complications. ALGS is a result of pathogenic variants in either JAG1 or NOTCH2 genes, which lead to the disruption of the Notch signaling pathway. Here, we present the case of a 17-year-old female patient, clinically and genetically diagnosed with ALGS1. MATERIAL AND
methodsThe 17-year-old patient, with an ALGS-free family history, was clinically diagnosed with ALGS due to liver dysfunction, cholestasis, kidney cysts, distinct craniofacial features, and skeletal malformations. Following genetic counseling and parental informed consent, genomic DNA was extracted from a sample of peripheral blood. Subsequently, whole-exome sequencing analysis was conducted, and clinically significant findings were additionally confirmed through Sanger DNA sequencing.
resultsThe genetic analysis revealed the presence of a likely pathogenic donor splice variant (c.2372+1G>C) in heterozygosity with the normal allele in the JAG1 gene at intronic position 1 of 493 (affecting splicing, MAF < 0.01), which was validated by Sanger sequencing. Bioinformatic analysis indicated that the detected donor splice variant may disrupt spliceosome recognition of the canonical splice site and lead to exon skipping.
conclusionBased on the clinical picture, personal/family history and genetic analyses, the patient was diagnosed with autosomal dominant ALGS type 1, caused by a de novo pathogenic mutation in the JAG1 gene. It is the first time this variant has been described in the relevant literature.
Indexed as
Identifiers
41273573What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.